Internal Pipeline
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
|---|---|---|---|---|---|
|
In development/Approved Preparing to initiate Out-licensed
|
|||||
| 1.Please visit www.KALBITOR.com for Important Safety Information and Full Prescribing Information including Boxed Warning and Medication Guide 2.Retinal Vein Occlusion (RVO). Partnered with Fovea Pharmaceuticals in EU 3.Licensed to sanofi aventis *Investigator-sponsored study for DX-88 in drug-induced angioedema **Compassionate-use of DX-88 in AAE | |||||
| KALBITOR® (ecallantide)1 | |||||
| Hereditary Angioedema (HAE) |
|||||
| DX-88 | |||||
| ACE inhibitor-induced angioedema* | |||||
| Acquired angioedema (AAE)** | |||||
| Retinal vein occlusion (RVO)induced macular edema2 | |||||
| DX-2240 | |||||
| Oncology3 | |||||
| DX-2400 | |||||
| Oncology | |||||